Core Points - Firefly Neuroscience, Inc. will be added to the Russell Microcap Index effective June 30, 2025, marking a significant milestone for the company since its Nasdaq listing less than a year ago [2][4] - The Russell indexes are utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] - The CEO of Firefly highlighted the company's achievements in 2025, including the discovery of a cognitive brain age biomarker, acceptance into the NVIDIA Connect program, and expansion through the acquisition of Evoke Neuroscience [4] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its FDA-cleared Brain Network Analytics (BNA™) technology [5] - The BNA™ technology is designed to enhance diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD [5] - Firefly has developed its BNA™ using AI and machine learning on a proprietary database of over 17,000 patients, providing clinicians with insights into brain function to improve diagnosis and treatment [6]
Firefly Neuroscience to be Added to the Russell Microcap® Index